Head to head
EVERESSE vs XERF (2026)
Compare purchase costs, running costs and the evidence behind each device.
Read the comparison overview
- Purchase cost
- No new-price range is on file for either EVERESSE or XERF. Request current quotes to compare purchase costs.
- Practice fit
- Both are listed under monopolar RF skin tightening. Check each model’s US regulatory status and labeled indications for your intended use.
Monopolar RF skin tightening
View full device profile →Monopolar RF skin tightening
View full device profile →Price comparison
New price range
- Classys EVERESSE (Volnewmer)
- Not published
- Cynosure Lutronic XERF
- Not published
Payback calculator
- Classys EVERESSE (Volnewmer)
- View cost details
- Cynosure Lutronic XERF
- View cost details
Next step
Supplies & running costs
Supplies & restrictions
- Classys EVERESSE (Volnewmer)
Read supply costs & requirements
Cartessa’s US store displayed $1,495 for the Everesse V-Tip Treatment Kit on October 7, 2026. The package includes one V-tip, four bottles of coupling gel and five grounding pads. This reference applies to that named kit; it does not establish treatments per tip, per-session quantities or a complete treatment cost. Confirm the applicable configuration, supplies, tax, shipping and availability in the written order.
Supply restrictions: marketed no-lock — manufacturer states no lock, expiry or metering
View running-cost details- Cynosure Lutronic XERF
Supply details not yet documented.
View running-cost details
FDA status & indications
FDA status & indication
- Classys EVERESSE (Volnewmer)
- FDA record cited — see scopeK240248
Record scope: 510(k): K240248 (Volnewmer, Classys, decision 29 Apr 2024) — Volnewmer is the cleared trade name. Checked 4 Sep 2026.
Read FDA indication wording
“Dermatologic procedures for electrocoagulation and hemostasis of soft tissue. Dermatologic and general surgical procedures for electrocoagulation and hemostasis of soft tissue. The Virtue RF System is intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis. Output Frequency 6.”
- Cynosure Lutronic XERF
- FDA record cited — see scopeK251327
Record scope: 510(k): K251327 (XERF, Lutronic, decision 11 Aug 2025). Checked 4 Sep 2026.
Read FDA indication wording
“XERF is indicated for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis.”
Which chains run each
Chain adoption
- Classys EVERESSE (Volnewmer)
- 0 recorded pairings
- Cynosure Lutronic XERF
- 0 recorded pairings
Chains using it
- Classys EVERESSE (Volnewmer)
- —
- Cynosure Lutronic XERF
- —
Approved reviews
- Classys EVERESSE (Volnewmer)
- 0
- Cynosure Lutronic XERF
- 1
Specs and platform
Manufacturer
- Classys EVERESSE (Volnewmer)
- Classys
- Cynosure Lutronic XERF
- Cynosure Lutronic
Built by (OEM)
- Classys EVERESSE (Volnewmer)
- Classys Inc.
- Cynosure Lutronic XERF
- Cynosure LLC
Category
- Classys EVERESSE (Volnewmer)
- Monopolar RF skin tightening
- Cynosure Lutronic XERF
- Monopolar RF skin tightening
Technology
- Classys EVERESSE (Volnewmer)
- Monopolar RF tightening platform; US brand EVERESSE, distributed by Cartessa (Radiofrequency — monopolar)
- Cynosure Lutronic XERF
- Monopolar RF skin tightening (Radiofrequency — monopolar)
Launch year
- Classys EVERESSE (Volnewmer)
- —
- Cynosure Lutronic XERF
- —
Status
- Classys EVERESSE (Volnewmer)
- Current
- Cynosure Lutronic XERF
- Current
Manufacturing relationship evidence
- Classys EVERESSE (Volnewmer)
- No separate manufacturing-relationship record linked.
- Cynosure Lutronic XERF
- No separate manufacturing-relationship record linked.
Current alternatives
Current catalog models in related categories. Confirm availability and configuration with the supplier.
Device and company names are trademarks of their respective owners. The Aesthetic Index is not affiliated with or endorsed by any manufacturer, distributor or lender named here, except as disclosed. Price figures are references, not current offers. Check each device’s source notes. Not medical, legal or regulatory advice.